Intriguingly, YAP1 is able to functionally compensate for oncogenic KRAS in colorectal and pancreatic cancer mouse models [48,49], which is consistent with the fact that RAS mutation and PKN1 mutation are mutually exclusive in the set of ERMS tumors presented here. Here, KRAS is linked to pancreatic neoplasm.